These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 29184856)

  • 21. Paradigm shift in the treatment options of hepatocellular carcinoma.
    Su TH; Hsu SJ; Kao JH
    Liver Int; 2022 Aug; 42(9):2067-2079. PubMed ID: 34515412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of IL-6Rα by ATF3 enhances IL-6 mediated sorafenib and regorafenib resistance in hepatocellular carcinoma.
    Dai Z; Wang X; Peng R; Zhang B; Han Q; Lin J; Wang J; Lin J; Jiang M; Liu H; Lee TH; Lu KP; Zheng M
    Cancer Lett; 2022 Jan; 524():161-171. PubMed ID: 34687791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond.
    Raoul JL; Kudo M; Finn RS; Edeline J; Reig M; Galle PR
    Cancer Treat Rev; 2018 Jul; 68():16-24. PubMed ID: 29783126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic therapy for hepatocellular carcinoma: beyond sorafenib.
    Boland P; Wu J
    Chin Clin Oncol; 2018 Oct; 7(5):50. PubMed ID: 30395717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nivolumab for Advanced Hepatocellular Carcinoma with Multiple Lung Metastases after Sorafenib Failure.
    Kim J; Chang JW; Park JY
    J Liver Cancer; 2020 Mar; 20(1):72-77. PubMed ID: 37383058
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan.
    Ogasawara S; Ooka Y; Itokawa N; Inoue M; Okabe S; Seki A; Haga Y; Obu M; Atsukawa M; Itobayashi E; Mizumoto H; Sugiura N; Azemoto R; Kanayama K; Kanzaki H; Maruta S; Maeda T; Kusakabe Y; Yokoyama M; Kobayashi K; Kiyono S; Nakamura M; Saito T; Suzuki E; Nakamoto S; Yasui S; Tawada A; Chiba T; Arai M; Kanda T; Maruyama H; Kato N
    Invest New Drugs; 2020 Feb; 38(1):172-180. PubMed ID: 31172442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
    Liao YJ; Hsu SM; Chien CY; Wang YH; Hsu MH; Suk FM
    Molecules; 2020 Jun; 25(12):. PubMed ID: 32575795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination.
    Tella SH; Kommalapati A; Mahipal A; Jin Z
    Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A narrative review of systemic treatment options for hepatocellular carcinoma: state of the art review.
    Awosika J; Sohal D
    J Gastrointest Oncol; 2022 Feb; 13(1):426-437. PubMed ID: 35284102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel?
    Mahipal A; Tella SH; Kommalapati A; Lim A; Kim R
    Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31366113
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.
    Wang EA; Stein JP; Bellavia RJ; Broadwell SR
    Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28758319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent Progress in Systemic Therapy for Hepatocellular Cancer (HCC).
    Ghaziani TT; Dhanasekaran R
    Curr Treat Options Gastroenterol; 2021 Jun; 19(2):351-368. PubMed ID: 35530750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemotherapy for hepatocellular carcinoma: current status and future perspectives.
    Ikeda M; Morizane C; Ueno M; Okusaka T; Ishii H; Furuse J
    Jpn J Clin Oncol; 2018 Feb; 48(2):103-114. PubMed ID: 29253194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systemic therapies for hepatocellular carcinoma.
    Ge S; Huang D
    Drug Discov Ther; 2015 Oct; 9(5):352-62. PubMed ID: 26632544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review.
    Ahmed F; Onwumeh-Okwundu J; Yukselen Z; Endaya Coronel MK; Zaidi M; Guntipalli P; Garimella V; Gudapati S; Mezidor MD; Andrews K; Mouchli M; Shahini E
    World J Gastrointest Oncol; 2021 Nov; 13(11):1813-1832. PubMed ID: 34853653
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sorafenib alone vs. sorafenib plus GEMOX as 1
    Assenat E; Pageaux GP; Thézenas S; Peron JM; Bécouarn Y; Seitz JF; Merle P; Blanc JF; Bouché O; Ramdani M; Poujol S; de Forges H; Ychou M; Boige V
    Br J Cancer; 2019 Apr; 120(9):896-902. PubMed ID: 30944458
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of hepatocellular carcinoma after progression on first-line systemic treatment: defining the optimal sequencing strategy in second line and beyond.
    Amaro CP; Tam VC
    Curr Oncol; 2020 Nov; 27(Suppl 3):S173-S180. PubMed ID: 33343211
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update.
    Kudo M
    Liver Cancer; 2020 Dec; 9(6):640-662. PubMed ID: 33442538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advances in pharmacotherapeutics for hepatocellular carcinoma.
    Cerrito L; Santopaolo F; Monti F; Pompili M; Gasbarrini A; Ponziani FR
    Expert Opin Pharmacother; 2021 Jul; 22(10):1343-1354. PubMed ID: 33637024
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.